71,544 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Oxbow Advisors LLC

Oxbow Advisors LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 71,544 shares of the biopharmaceutical company’s stock, valued at approximately $4,909,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Institute for Wealth Management LLC. boosted its stake in Gilead Sciences by 1.9% in the 2nd quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company’s stock worth $518,000 after purchasing an additional 142 shares in the last quarter. First Affirmative Financial Network lifted its stake in shares of Gilead Sciences by 3.5% in the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 147 shares in the last quarter. Rathbones Group PLC lifted its stake in shares of Gilead Sciences by 3.7% in the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 150 shares in the last quarter. MCF Advisors LLC increased its position in shares of Gilead Sciences by 2.1% during the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock valued at $538,000 after acquiring an additional 152 shares in the last quarter. Finally, Westside Investment Management Inc. raised its holdings in Gilead Sciences by 0.6% in the 2nd quarter. Westside Investment Management Inc. now owns 26,526 shares of the biopharmaceutical company’s stock worth $1,826,000 after acquiring an additional 152 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on GILD. Truist Financial lifted their target price on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Royal Bank of Canada boosted their target price on Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a report on Friday, August 9th. Robert W. Baird reissued a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. Finally, BMO Capital Markets increased their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Twelve equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $82.06.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded down $0.05 during trading hours on Friday, hitting $78.72. The company’s stock had a trading volume of 9,220,980 shares, compared to its average volume of 7,163,236. The company has a market cap of $98.07 billion, a PE ratio of 218.67, a PEG ratio of 2.74 and a beta of 0.18. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The business has a 50 day moving average price of $74.06 and a two-hundred day moving average price of $70.57. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.91%. Gilead Sciences’s payout ratio is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.